Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Regenxbio reports the discovery of nodules and masses on the spines of patients enrolled in a trial for RGX-121, the company's investigational therapy for Hunter syndome.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。